Enrollment

Assessed for eligibility (N=39)

Randomized (N=39)

Allocation

Allocated to quetiapine group (N=26)
- Received allocated intervention (N=23)
- Did not receive allocated intervention (withdrew informed consent) (N=3)

Allocated to placebo group (N=13)
- Received allocated intervention (N=13)

Follow-Up

Discontinued intervention (N=10)
- Lost to follow-up (N=1)
- Adverse event (N=4)
- Protocol noncompliance (N=2)
- Lack of efficacy (N=3)

Discontinued intervention (N=5)
- Adverse event (N=3)
- Lack of efficacy (N=2)

Analysis

Completed study (N=13)
Intention-to-treat population (N=22)
- GAD (N=10) and MDD (N=12)

Completed study (N=8)
Intention-to-treat population (N=13)
- GAD (N=7) and MDD (N=6)